RxDoctor Payments DataLook up a doctor →

Rita Jermyn, MD

Advanced Heart Failure and Transplant Cardiology · Roslyn, NYNPI 1811140627

Payments from drug & device makers

$992,586in general payments, 2019–2025

Across 641 payments — averaging $1548.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$317K
  • Abbott$248K
  • Edwards Lifesciences$133K
  • Medtronic$75K
  • Cvrx, Inc.$62K
  • Bayer$56K
  • plus $103K from 27 others

What the payments were for

  • Consulting fees$29,39034%
  • Speaking & faculty fees$39,86346%
  • Grants$1,2221%
  • Travel & lodging$5,7937%
  • Food & beverage$10,48412%
  • Education$2060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$992,586 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

See all advanced heart failure and transplant cardiology providers in New York

Medicare billing

Part B allowed, 2024
$273,517
Medicare patients
732
Services billed
3,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan66$886,599
EntrestoSacubitril/Valsartan169$278,030
JardianceEmpagliflozin64$102,083
FarxigaDapagliflozin Propanediol61$72,759
EliquisApixaban54$68,341
XareltoRivaroxaban17$19,862
Bosentan14$16,284
VeltassaPatiromer Calcium Sorbitex12$12,539
Bumetanide74$3,509
Metoprolol Succinate173$3,108
Torsemide94$2,029
Amiodarone Hcl11$1,200
Eplerenone14$1,142
Spironolactone155$1,078
Ezetimibe46$1,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan$123$902,88380 claims
NovartisEntresto$316,702$278,030169 claims
Boehringer IngelheimJardiance$37,677$102,08364 claims
AstraZenecaFarxiga$72$72,75961 claims
PfizerEliquis$18$68,34154 claims
Johnson & JohnsonXarelto$250$19,86217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

Other advanced heart failure and transplant cardiology in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →